Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: triamcinolone Clear all
Completed Not applicable Interventional Results available

Clinical Study of Safety and Efficacy for the Relieva Stratus With Elution of Triamcinolone Acetonide

NCT00791934
View directory record Official record
Conditions
Sinusitis
Interventions
Stratus Microflow Ethmoid Spacer
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 21, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional

Topical Treatment for Atopic Dermatitis

NCT06244212
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
9 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Not applicable Interventional Results available

Intraarticular Corticosteroid Therapy in Perthes Disease.

NCT01026909
View directory record Official record
Conditions
Legg-Calve Perthes Disease
Interventions
Aristospan 20mg
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
4 Years to 13 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Phase 4 Interventional Results available

Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

NCT02920177
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Steroid Injection vs. BioDRestore for Patients With Knee OA

NCT02767492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
BioD Restore, Kenalog
Device · Drug
Lead sponsor
The Hawkins Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

NCT01323920
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndrome
Interventions
Bortezomib, Tacrolimus, Methotrexate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Results available

Effect of Steroid Injections in a Knee With Osteoarthritis

NCT01230424
View directory record Official record
Conditions
Osteoarthritis (OA) of the Knee
Interventions
Triamcinolone Acetonide, 0.9% Sodium Chloride Injection as Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 21, 2026, 4:13 AM EDT
Withdrawn Phase 1 Interventional

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

NCT04655391
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia
Interventions
Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate, Gilteritinib Fumarate, Glasdegib Maleate, Ivosidenib, Venetoclax
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

NCT00464347
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Kybella With Triamcinolone

NCT03361176
View directory record Official record
Conditions
Adiposity
Interventions
Injectable sodium deoxycholate, Injectable sodium deoxycholate with Triamcinolone acetate
Drug · Combination Product
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Diego, California • Hunt Valley, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Phase 4 Interventional Results available

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

NCT03636373
View directory record Official record
Conditions
Gout Attack
Interventions
Etanercept, Triamcinolone Acetonide
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 1 Interventional

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

NCT04053283
View directory record Official record
Conditions
Metastatic Cancer, Epithelial Tumor
Interventions
NG-641
Biological
Lead sponsor
Akamis Bio
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Santa Barbara, California • Celebration, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients

NCT00311311
View directory record Official record
Conditions
Atherosclerosis, Kidney Failure
Interventions
tacrolimus, mycophenolate mofetil, prednisone, sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 21, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

NCT06790784
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MINDSpeed Food and Brain Training RCT

NCT03419052
View directory record Official record
Conditions
Low Education, Cognition, Cognitive Training, Polyphenols
Interventions
Speed of processing training, MIND foods, Cognitive training control, Control foods
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
60 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

NCT00887536
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, docetaxel, doxorubicin, cyclophosphamide, pegfilgrastim
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years to 70 Years · Female only
Enrollment
1,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
522
States / cities
Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2021 · Synced Sep 21, 2026, 4:13 AM EDT
Terminated Phase 1 Interventional

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058
View directory record Official record
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study

NCT00105027
View directory record Official record
Conditions
Macular Edema, Cystoid, Retinal Vein Occlusion
Interventions
Standard Care, intravitreal triamcinolone injection
Other · Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Not applicable Interventional Results available

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

NCT00746889
View directory record Official record
Conditions
Osteoarthritis
Interventions
triamcinolone acetonide, saline
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

Study of Daclizumab in Patients With Chronic, Persistent Asthma

NCT00028288
View directory record Official record
Conditions
Asthma
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 21, 2026, 4:13 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer

NCT03794635
View directory record Official record
Conditions
Metastatic Cancer, Locally Advanced Cancer, Thoracic Cancer, Gynecologic Cancer, Genitourinary Cancer, Lymphoma
Interventions
Weekly 45 minute Sessions
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 21, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

LMB-2 to Treat Hairy Cell Leukemia

NCT00321555
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 21, 2026, 4:13 AM EDT